• Ocular Therapeutix Inc., of Bedford, Mass., said its travoprost punctum plug will be tested in a pilot Phase II trial to examine a two-month sustained-release drug (OTX-TP2) for ocular hypertension and glaucoma.
To continue reading subscribe now to BioWorld Today
